## Financial Results for FY2018 \& Outlook for FY2019

May 15, 2019
SUMITOMO CHEMICAL

## (Cautionary Statement)

Statements made in this material with respect to Sumitomo Chemical's current plans, estimates, strategies and beliefs that are not historical facts are forward-looking statements about the future performance of Sumitomo Chemical. These statements are based on management's assumptions and beliefs in light of the information currently available to it, and involve risks and uncertainties. The important factors that could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to, general economic conditions in Sumitomo Chemical's markets; demand for, and competitive pricing pressure on, Sumitomo Chemical's products in the marketplace;
Sumitomo Chemical's ability to continue to win acceptance for its products in these highly competitive markets; and movements of currency exchange rates.

## Contents

1. Consolidated Financial Results for FY2018 Ended March 31, 2019
Financial Summary ..... 4
Sales revenue by Business segment ..... 5
Core Operating Income by Business segment ..... 6
Segment Analysis ..... 7
Breakdown of Non-recurring Items ..... 12
Consolidated Balance Sheets ..... 13
Consolidated Statements of Cash Flows ..... 14
2. Outlook for FY2019
Financial Summary ..... 16
Sales revenue by Business segment ..... 17
Core Operating Income by Business segment ..... 18
Segment Analysis ..... 19
Consolidated Statements of Cash Flows ..... 24
(Reference: Segment Information)
Segment Topics ..... 26
Sales revenue by Business segment (Quarterly) ..... 27
Core Operating Income by Business segment (Quarterly) ..... 28
Cost Elements etc. ..... 29
Capital Expenditures by Business segment ..... 30
Estimated Capital Expenditures
by Business segment ..... 31
Depreciation and Amortization by Business segment ..... 32
Estimated Depreciation and Amortization by Business segment ..... 33
Research \& Development Expenses by Business segment ..... 34
Estimated Research \& Development Expenses by Business segment ..... 35
Major Group Companies ..... 36
Overseas Sales revenue ..... 37
Sales revenue / Profits Transition ..... 38
Interest-bearing Liabilities / D/E Ratio Transition ..... 39
Cash Dividends / Payout Ratio Transition ..... 40

## 1. Consolidated Financial Results for FY2018 Ended March 31, 2019

## Financial Summary

|  |  |  |  | lions of yen |
| :---: | :---: | :---: | :---: | :---: |
|  | FY2017 | FY2018 | Difference | Ratio |
| Sales revenue | 2,190.5 | 2,318.6 | 128.1 | 5.8\% |
| Core operating income | 262.7 | 204.3 | -58.4 | -22.2\% |
| (Equity in earnings) | (55.3) | (37.2) | (-18.1) | - |
| Non-recurring items | -11.8 | -21.3 | -9.5 |  |
| Operating income | 250.9 | 183.0 | -68.0 | -27.1\% |
| Finance income/expenses | -10.1 | 5.4 | 15.5 |  |
| (Gain/loss on foreign currency transactions) | (-9.6) | (5.5) | (15.1) |  |
| Income tax expenses | -62.7 | -35.9 | 26.7 |  |
| Net income attributable to non-controlling interests | -44.4 | -34.5 | 9.9 |  |
| Net income attributable to owners of the parent | 133.8 | 118.0 | -15.8 | -11.8\% |
| ROE | 15.4\% | 12.3\% |  |  |
| Exchange rate(yen/\$) | 110.85 | 110.92 |  |  |
| Naphtha price(yen/KL) | 41,900 | 49,500 |  |  |
| Overseas sales revenue ratio | 63.2\% | 64.9\% |  |  |

## Sales revenue by Business segment

|  |  |  |  |  |  | Unit; billions of yen |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | FY2017 | FY2018 | Difference | Ratio | $\begin{gathered} \text { Sales } \\ \text { Price } \\ \text { Variance } \end{gathered}$ | Shipping Volume Variance | Foreign Currency Conversion Variance |
| Petrochemicals \& Plastics | 674.1 | 757.5 | 83.4 | 12.4\% | 29.5 | 53.9 | 0.0 |
| Energy \& Functional Materials | 251.0 | 282.9 | 31.9 | 12.7\% | 9.0 | 23.1 | -0.2 |
| IT-related Chemicals | 368.7 | 396.8 | 28.1 | 7.6\% | -10.0 | 41.5 | -3.4 |
| Health \& Crop Sciences | 339.7 | 338.1 | -1.6 | -0.5\% | -5.5 | 11.2 | -7.3 |
| Pharmaceuticals | 500.2 | 492.1 | -8.1 | -1.6\% | -8.4 | 0.4 | -0.1 |
| Others \& Adjustments | 56.8 | 51.1 | -5.6 | -9.9\% | 0.0 | -5.6 | 0.0 |
| Total | 2,190.5 | 2,318.6 | 128.1 | 5.8\% | 14.6 | 124.6 | -11.1 |

Analysis


SUMITOMO CHEMICAL

## Core Operating Income by Business segment



## Analysis



SUMITOMO CHEMICAL

## Petrochemicals \& Plastics - Segment Analysis -

## Sales revenue



## Total $¥ 757.5$ billion ( +83.4 from FY2017 )

Sales price +29.5

Volume +53.9

Foreign exchange

$$
0.0
$$

- Rise in market prices
- Increase in shipments of Rabigh products


## Core Operating Income Total $¥ 61.6$ billion ( -33.0 from FY2017)



Price variance
-6.0

- Decrease in profit margin on petrochemical products and synthetic resins

Cost variance
$+1.0$
Volume variance etc.
-28.0

- Decrease in equity in earnings of affiliates
- Decrease in shipments due to periodic plant maintenance in the Chiba works and Singapore
- Decrease in license revenue


## Energy \& Functional Materials - Segment Analysis -

Sales revenue


## Total ¥282.9 billion (+31.9 from FY2017)

Sales price +9.0

- Higher market price for aluminum
- Increase in shipments of lithium-ion secondary battery separators
- Increase in shipments of high purity alumina

Foreign exchange
-0.2

Core Operating Income Total $¥ 23.0$ billion ( +3.8 from FY2017)


## IT-related Chemicals - Segment Analysis -

## Sales revenue



## Total $¥ 396.8$ billion (+28.1 from FY2017)

Sales price -10.0

- Decline in the selling price of polarizing film
- Increase in shipments of polarizing film
- Increase in shipments of touchscreen panels

Foreign exchange
-3.4

## Core Operating Income Total $¥ 26.2$ billion ( +13.9 from FY2017)



Price variance

- Decline in the selling price of polarizing film

Cost variance

- Rationalization of the use of raw materials
+10.0 - Improvement of production yields

Volume variance etc. $\quad$ Increase in shipments of polarizing film
+14.4 - Increase in shipments of touchscreen panels

## Health \& Crop Sciences - Segment Analysis -



## Pharmaceuticals - Segment Analysis -



## Core Operating Income Total $¥ 80.8$ billion ( -14.0 from FY2017)



Price variance

- NHI price revisions in Japan

Cost variance
+3.5

Volume variance etc. - One time gain from divestiture of ciclesonide
-9.1 products in FY2017

## Breakdown of Non-recurring Items

Unit; billions of yen

|  | FY2017 | FY2018 | Difference |
| :---: | :---: | :---: | :---: |
| Impairment loss | -12.4 | -24.6 | -12.3 |
| Restructuring charges | -14.2 | -9.1 | 5.1 |
| Changes in fair value of contingent consideration | 6.1 | 9.0 | 2.8 |
| Reversal of impairment loss | 3.5 | 3.0 | -0.5 |
| Gain on sale of property, plant and equipment | 6.8 | 1.4 | -5.4 |
| Others | -1.6 | -0.9 | 0.7 |
| Non-recurring items | -11.8 | -21.3 | -9.5 |

## Consolidated Balance Sheets

|  |  |  |  | Unit; billions of yen |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 31-Mar-18 | 31-Mar-19 | Difference |  | 31-Mar-18 | 31-Mar-19 | Difference |
| Current assets | 1,254.8 | 1,291.2 | 36.4 | Liabilities | 1,816.5 | 1,819.7 | 3.3 |
| Cash and cash equivalents | 231.9 | 201.7 | -30.3 | Trade and other payables | 486.8 | 482.9 | -4.0 |
| Trade and other receivables | 530.6 | 550.0 | 19.4 | Interest-bearing Liabilities | 842.2 | 839.5 | -2.6 |
| Inventories | 446.8 | 489.3 | 42.5 | Others | 487.5 | 497.3 | 9.9 |
| Others | 45.5 | 50.3 | 4.8 | Equity | 1,252.2 | 1,351.9 | 99.7 |
| Non-current assets | 1,813.9 | 1,880.4 | 66.5 | Shareholders' equity | 842.0 | 922.3 | 80.3 |
| Property, plant and equipment | 675.7 | 735.9 | 60.2 | Other components of equity | 85.2 | 76.4 | -8.7 |
| Goodwill and Intangible assets | 355.5 | 343.5 | -12.0 | Non-controlling interests | 325.1 | 353.2 | 28.1 |
| Others | 782.6 | 801.0 | 18.3 |  |  |  |  |
| Total | 3,068.7 | 3,171.6 | 102.9 | Total | 3,068.7 | 3,171.6 | 102.9 |
|  |  |  |  | Equity attributable to owners of parent to total assets | 30.2\% | 31.5\% | 1.3\% |
|  |  |  |  | D/E ratio (times) | 0.7 | 0.6 | -0.1 |

## SUMITOMO CHEMICAL

## Consolidated Statements of Cash Flows

|  | Unit; billions of yen |  |  |
| :---: | :---: | :---: | :---: |
|  | FY2017 | FY2018 | Difference |
| Cash flows from operating activities | 293.3 | 208.1 | -85.1 |
| Cash flows from investing activities | -154.5 | -180.8 | -26.3 |
| Free cash flows | 138.7 | 27.3 | -111.4 |
| Cash flows from financing activities | -94.3 | -60.9 | 33.4 |
| Effect of exchange rate changes on cash and cash equivalents | -5.8 | 3.3 | 9.1 |
| Net change in cash and cash equivalents | 38.6 | -30.3 | -68.9 |
| Cash and cash equivalents at end of year | 231.9 | 201.7 | -30.3 |

## 2. Outlook for FY2019

## Financial Summary

Unit; billions of yen

|  | FY2018 | $\begin{gathered} \text { FY2019 } \\ \text { (estimated) } \end{gathered}$ | Difference | Ratio |
| :---: | :---: | :---: | :---: | :---: |
| Sales revenue | 2,318.6 | 2,440.0 | 121.4 | 5.2\% |
| Core operating income | 204.3 | 205.0 | 0.7 | 0.4\% |
| (Equity in earnings) | (37.2) | (23.0) | (-14.2) | - |
| (Non-recurring items) | (-21.3) | (-15.0) | (6.3) | - |
| Operating income | 183.0 | 190.0 | 7.0 | 3.8\% |
| Net income attributable to owners of the parent | 118.0 | 100.0 | -18.0 | -15.2\% |
| ROE | 12.3\% | 9.7\% |  |  |
| Exchange rate(yen/\$) | 110.92 | 110.00 |  |  |
| Naphtha price(yen/KL) | 49,500 | 43,000 |  |  |

## Sales revenue by Business segment

| Unit; billions of yen |  |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | FY2018 | FY2019 (estimated) | Difference | Ratio | Sales Price Variance | Shipping <br> Volume <br> Variance | Foreign Currency Conversion Variance |
| Petrochemicals \& Plastics | 757.5 | 765.0 | 7.5 | 1.0\% | -65.0 | 75.2 | -2.7 |
| Energy \& Functional Materials | 282.9 | 310.0 | 27.2 | 9.6\% | 3.5 | 22.9 | 0.8 |
| IT-related Chemicals | 396.8 | 425.0 | 28.2 | 7.1\% | -29.5 | 51.4 | 6.3 |
| Health \& Crop Sciences | 338.1 | 390.0 | 51.9 | 15.4\% | -1.5 | 55.1 | -1.7 |
| Pharmaceuticals | 492.1 | 495.0 | 2.9 | 0.6\% | 0.0 | 2.9 | 0.0 |
| Others \& Adjustments | 51.1 | 55.0 | 3.9 | 7.6\% | 0.0 | 3.9 | 0.0 |
| Total | 2,318.6 | 2,440.0 | 121.4 | 5.2\% | -92.5 | 211.2 | 2.7 |

## Analysis



## Core Operating Income by Business segment




## Petrochemicals \& Plastics - Segment Analysis -

## Sales revenue Total $¥ 765.0$ billion ( +7.5 from FY2018)



- Lower market prices
- Increase in shipments of Rabigh products
- Increase in shipment volume after the FY2018 periodic plant maintenance in the Chiba works and Singapore


## Core Operating Income Total $¥ 40.0$ billion ( -21.6 from FY2018)



## Energy \& Functional Materials - Segment Analysis -

## Sales revenue



## Total $¥ 310.0$ billion ( +27.2 from FY2018)

Sales price +3.5

Volume

- Higher market price for aluminum
- Increase in shipments of lithium-ion secondary battery separators
- Increase in shipment volume after the FY2018 periodic plant maintenance in the Chiba works

Foreign exchange

$$
+0.8
$$

## Core Operating Income Total $¥ 25.0$ billion ( +2.0 from FY2018)



Price variance
-3.5

- Decrease in profit margins on advanced polymers

Cost variance
-1.0
Volume variance etc. Increase in shipments of lithium-ion secondary battery separators
+6.5 - Increase in shipment volume after the FY2018 periodic plant maintenance in the Chiba works

## IT-related Chemicals - Segment Analysis -

## Sales revenue



## Total $¥ 425.0$ billion ( +28.2 from FY2018)

Sales price
-29.5

- Decline in the selling price of polarizing film
- Decline in the selling price of touchscreen panels

Volume

- Increase in shipments of polarizing film
+51.4 - Increase in shipments of touchscreen panels
- Increase in shipments of high-purity chemicals for Semiconductors


## Core Operating Income Total $¥ 27.0$ billion ( +0.8 from FY2018)



## Health \& Crop Sciences - Segment Analysis -

## Sales revenue



## Total $¥ 390.0$ billion ( +51.9 from FY2018)

Sales price

$$
-1.5
$$

Volume +55.1

- Increase in shipments of crop protection chemicals due to the recovery from the negative influence of extreme weather in FY2018.


## Core Operating Income Total $¥ 37.0$ billion ( +17.3 from FY2018)



Price variance
0.0

Cost variance
-4.5

- Launch of new production line of feed additive methionine

Volume variance etc.
+21.8

- Increase in shipments of feed additive methionine
- Increase in shipments of crop protection chemicals due to the recovery from the negative influence of extreme weather in FY2018.


## Pharmaceuticals - Segment Analysis -

## Sales revenue



## Total ¥495.0 billion (+2.9 from FY2018)

Sales price
0.0

Volume - Increase in shipments of Latuda® in North +2.9 America

- Decrease in shipments of long-listed brands in Japan

Foreign exchange

## Core Operating Income Total $¥ 81.0$ billion ( +0.2 from FY2018)

Price variance
0.0

Cost variance - Decrease in sales expenses
+2.0 - Increase in R\&D expenses

Volume variance etc. - Decrease in shipments of long-listed brands
-1.8 in Japan

## Consolidated Statements of Cash Flows

Unit; billions of yen

|  | FY2018 | FY2019 <br> (estimated) | Difference |
| :--- | ---: | ---: | ---: |
| Cash flows from operating activities | 208.1 | $\mathbf{2 2 0 . 0}$ | 11.9 |
| Cash flows from investing activities | -180.8 | $\mathbf{- 3 4 0 . 0}$ | -159.1 |
| Free cash flows | 27.3 | $\mathbf{- 1 2 0 . 0}$ | -147.3 |
| Cash flows from financing activities | -60.9 | $\mathbf{1 6 5 . 0}$ | $\mathbf{2 2 5 . 9}$ |
| Effect of exchange rate changes on <br> cash and cash equivalents | 3.3 | $\mathbf{0 . 0}$ | -3.3 |
| Net change in cash and cash equivalents | -30.3 | $\mathbf{4 5 . 0}$ | $\mathbf{7 5 . 2}$ |
| Interest-bearing debt balance | $\mathbf{8 3 9 . 5}$ | $\mathbf{1 , 0 5 0 . 0}$ | $\mathbf{2 1 0 . 5}$ |

## (Reference: Segment Information)

## Segment Topics

| Petrochemicals \& Plastics | - Started the shipment of products from the Rabigh Phase 2 Project <br> - Decided to restart a Methyl Methacrylate production line in Singapore |
| :---: | :---: |
| Energy \& Functional Materials | - Expanded production capacity for Polyether Sulfone (PES) <br> - Decided to expand production capacity for cathode materials (Tanaka Chemical Corp.) |
| IT-related Chemicals | - Expanded production capacity for high-purity chemicals for semiconductors in China (Changzhou/Xi'an) <br> - A polarizing film manufacturing company in China became a wholly owned subsidiary <br> - Acquired shares of JOLED |
| Health \& Crop Sciences | - Completed construction of a new production line for feed additive methionine <br> - Decided to merge group companies in India <br> - Expanded R\&D facilities (CRC in Takarazuka, BRC in VBC) |
| Pharmaceuticals | - Resolution of disputes under a consolidated patent infringement lawsuit regarding ANDAs for LATUDA in the U.S. (One case is pending) <br> - Efforts toward regenerative medicine through collaboration with Kyoto University's Center for iPS Cell Research and Application (CiRA). |

## Sales revenue by Business segment (Quarterly)

|  | FY2017 |  |  |  | FY2018 |  |  |  | FY2019 (estimated) |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 1Q | 2Q | 3Q | 4Q | 1Q | 2Q | 3Q | 4Q | 1st Half | 2nd Half |
| Petrochemicals \& Plastics | 153.5 | 166.6 | 176.5 | 177.5 | 185.6 | 194.8 | 196.5 | 180.6 | 385.0 | 380.0 |
| Energy \& Functional Materials | 59.6 | 60.6 | 67.5 | 63.2 | 68.5 | 72.3 | 73.8 | 68.2 | 150.0 | 160.0 |
| IT-related Chemicals | 90.8 | 97.8 | 98.1 | 82.1 | 89.2 | 106.3 | 105.5 | 95.9 | 210.0 | 215.0 |
| Health \& Crop Sciences | 67.5 | 70.2 | 78.5 | 123.5 | 69.4 | 68.8 | 74.5 | 125.4 | 165.0 | 225.0 |
| Pharmaceuticals | 124.6 | 123.5 | 132.3 | 119.8 | 124.3 | 118.4 | 129.1 | 120.3 | 245.0 | 250.0 |
| Others \& Adjustments | 12.0 | 13.7 | 12.6 | 18.5 | 11.9 | 12.7 | 12.6 | 14.0 | 25.0 | 30.0 |
| Total | 507.9 | 532.4 | 565.5 | 584.6 | 548.9 | 573.2 | 592.0 | 604.4 | 1,180.0 | 1,260.0 |

## Core Operating Income by Business segment (Quarterly)

Unit; billions of yen

|  | FY2017 |  |  |  | FY2018 |  |  |  | FY2019 (estimated) |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 1 Q | 2 Q | 30 | 4 Q | 10 | 2 Q | 30 | 4Q | 1st Halif | 2nd Half |
| Petrochemicals \& Plastics | 15.0 | 26.8 | 28.9 | 23.9 | 17.8 | 17.6 | 16.4 | 9.8 | 19.0 | 21.0 |
| Energy \& Functional Materials | 4.8 | 5.5 | 5.6 | 3.3 | 5.9 | 6.9 | 7.4 | 2.8 | 12.5 | 12.5 |
| IT-related Chemicals | 3.3 | 5.7 | 4.6 | -1.2 | 4.3 | 10.5 | 7.5 | 3.9 | 13.5 | 13.5 |
| Health \& Crop Sciences | 5.5 | 2.9 | 10.3 | 25.3 | 2.6 | -0.2 | 1.5 | 15.8 | 0.0 | 37.0 |
| Pharmaceuticals | 25.9 | 32.2 | 23.5 | 13.2 | 19.7 | 19.6 | 20.0 | 21.5 | 40.0 | 41.0 |
| Others \& Adjustments | -1.1 | 0.4 | -0.9 | -0.5 | -2.1 | -0.6 | 0.1 | -4.4 | -5.0 | 0.0 |
| Total | 53.5 | 73.5 | 71.8 | 63.8 | 48.2 | 53.9 | 52.8 | 49.3 | 80.0 | 125.0 |

## Cost Elements etc.

|  | Unit; billions of yen <br> FY2019 |  |  |
| :--- | ---: | ---: | ---: | ---: |
| Capital Expenditures | FY2017 | FY2018 | (estimated) |
| Depreciation and Amortization | 158.8 | 163.7 | 153.0 |
| Research \& Development Expenses | 107.1 | 112.5 | 135.0 |
| Number of Employees (as of March 31) | 165.3 | 163.5 | 175.0 |

## Capital Expenditures by Business segment

Unit; billions of yen

|  | FY2017 | FY2018 | Difference |
| :---: | :---: | :---: | :---: |
| Petrochemicals \& Plastics | 17.4 | 31.5 | 14.1 |
| Energy \& Functional Materials | 22.5 | 24.3 | 1.8 |
| IT-related Chemicals | 24.5 | 33.6 | 9.1 |
| Health \& Crop Sciences | 56.3 | 39.9 | -16.4 |
| Pharmaceuticals | 21.2 | 16.9 | -4.4 |
| Others \& Adjustments | 16.8 | 17.6 | 0.7 |
| Total | 158.8 | 163.7 | 4.8 |

## Estimated Capital Expenditures by Business segment

Unit; billions of yen

|  | FY2018 | FY2019 <br> (estimated) | Difference |
| :--- | ---: | ---: | ---: |
| Petrochemicals \& Plastics | 31.5 | $\mathbf{2 9 . 5}$ | -2.0 |
| Energy \& Functional Materials | $\mathbf{2 4 . 3}$ | $\mathbf{3 1 . 0}$ | 6.7 |
| IT-related Chemicals | 33.6 | $\mathbf{4 4 . 0}$ | 10.5 |
| Health \& Crop Sciences | 39.9 | $\mathbf{1 8 . 5}$ | -21.4 |
| Pharmaceuticals | 16.9 | $\mathbf{1 3 . 0}$ | -3.9 |
| Others \& Adjustments | 17.6 | $\mathbf{1 7 . 0}$ | -0.6 |
| Total | $\mathbf{1 6 3 . 7}$ | $\mathbf{1 5 3 . 0}$ | -10.7 |

## Depreciation and Amortization by Business segment

|  | Unit; billions of yen |  |  |
| :---: | :---: | :---: | :---: |
|  | FY2017 | FY2018 | Difference |
| Petrochemicals \& Plastics | 23.0 | 22.0 | -0.9 |
| Energy \& Functional Materials | 13.9 | 15.4 | 1.5 |
| IT-related Chemicals | 29.6 | 31.1 | 1.5 |
| Health \& Crop Sciences | 16.2 | 18.7 | 2.5 |
| Pharmaceuticals | 15.1 | 16.3 | 1.2 |
| Others \& Adjustments | 9.4 | 9.0 | -0.4 |
| Total | 107.1 | 112.5 | 5.4 |

## Estimated Depreciation and Amortization by Business segment

Unit; billions of yen

|  | FY2018 | FY2019 <br> (estimated) | Difference |
| :--- | ---: | ---: | ---: |
| Petrochemicals \& Plastics | 22.0 | $\mathbf{2 6 . 5}$ | $\mathbf{4 . 5}$ |
| Energy \& Functional Materials | 15.4 | $\mathbf{1 6 . 0}$ | 0.6 |
| IT-related Chemicals | 31.1 | $\mathbf{3 4 . 5}$ | 3.4 |
| Health \& Crop Sciences | 18.7 | $\mathbf{2 5 . 5}$ | 6.8 |
| Pharmaceuticals | 16.3 | $\mathbf{1 9 . 5}$ | 3.2 |
| Others \& Adjustments | 9.0 | $\mathbf{1 3 . 0}$ | $\mathbf{4 . 0}$ |
| Total | $\mathbf{1 1 2 . 5}$ | $\mathbf{1 3 5 . 0}$ | $\mathbf{2 2 . 5}$ |

## Research \& Development Expenses by Business segment

|  | Unit; billions of yen |  |  |
| :---: | :---: | :---: | :---: |
|  | FY2017 | FY2018 | Difference |
| Petrochemicals \& Plastics | 6.6 | 7.1 | 0.4 |
| Energy \& Functional Materials | 7.5 | 8.5 | 1.0 |
| IT-related Chemicals | 17.3 | 17.3 | -0.0 |
| Health \& Crop Sciences | 29.3 | 29.3 | 0.0 |
| Pharmaceuticals | 89.3 | 85.1 | -4.3 |
| Others \& Adjustments | 15.3 | 16.2 | 0.9 |
| Total | 165.3 | 163.5 | -1.9 |

Unit; billions of yen

|  | FY2018 | FY2019 <br> (estimated) | Difference |
| :--- | ---: | ---: | ---: |
| Petrochemicals \& Plastics | 7.1 | $\mathbf{7 . 5}$ | 0.4 |
| Energy \& Functional Materials | 8.5 | $\mathbf{8 . 5}$ | 0.0 |
| IT-related Chemicals | 17.3 | $\mathbf{1 8 . 0}$ | 0.7 |
| Health \& Crop Sciences | 29.3 | $\mathbf{3 4 . 0}$ | 4.7 |
| Pharmaceuticals | 85.1 | $\mathbf{8 9 . 0}$ | 3.9 |
| Others \& Adjustments | 16.2 | $\mathbf{1 8 . 0}$ | $\mathbf{1 . 8}$ |
| Total | 163.5 | $\mathbf{1 7 5 . 0}$ | 11.5 |

## Major Group Companies

| Company | Sales Revenue |  | Profit Trends |
| :---: | :---: | :---: | :---: |
|  | FY2017 | FY2018 |  |
| The Polyolefin Company (Singapore) <br> (millions of USD) | 1,179 | 1,146 | Decreased margins and decreased sales volume due to periodic plant maintenance in the current term. |
| Petrochemical Corporation of Singapore <br> (millions of USD) | 2,692 | 2,770 | Decreased margins and decreased sales volume due to periodic plant maintenance in the current term. |
| Rabigh Refining and Petrochemical Company | 34,211 | 40,998 | Lower margin on oil refining. |
| Dongwoo Fine-Chem <br> (billions of KRW) | 2,160.8 | 2,383.2 | Increased due to higher sales volume and other factors despite lower selling price. |
| Valent U.S.A. and Subsidiaries <br> (millions of USD) | 915 | 848 | Weather conditions have created market delays and reduced market opportunities. |



## Sales revenue / Profits Transition

## Sales revenue

## Profit




## Cash Dividends / Payout Ratio Transition

## Dividends per share



